BioCentury
ARTICLE | Clinical News

Allogeneic aNK cells: Ph I QUILT-3.018 data

January 27, 2017 4:37 AM UTC

Data from 7 patients with relapsed or refractory AML in the open-label, U.S. Phase I QUILT-3.018 trial showed that 1×109 and 3×109 IV aNK cells/m2 led to no dose-limiting toxicities (DLTs) or grade 3/...

BCIQ Company Profiles

NantKwest Inc.